Browse by author
Lookup NU author(s): Dr Dennis LendremORCiD,
Dr Clare LendremORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
By quickly clearing the development pipeline of failing or marginal products, fast-fail strategies release resources to focus on more promising molecules. The Quick-Kill model of drug development demonstrates that fast-fail strategies will: (1) reduce the expected time to market; (2) reduce expected R&D costs; and (3) increase R&D productivity. This paper outlines the model and demonstrates the impact of fast-fail strategies. The model is illustrated with costs and risks data from pharmaceutical and biopharmaceutical companies.
Author(s): Lendrem DW, Lendrem BC
Publication type: Article
Publication status: Published
Journal: Drug Discovery Today
Print publication date: 12/12/2012
ISSN (print): 1359-6446
ISSN (electronic): 1878-5832
Altmetrics provided by Altmetric